[go: up one dir, main page]

KR960010635A - 약제학적 화합물 - Google Patents

약제학적 화합물 Download PDF

Info

Publication number
KR960010635A
KR960010635A KR1019950029475A KR19950029475A KR960010635A KR 960010635 A KR960010635 A KR 960010635A KR 1019950029475 A KR1019950029475 A KR 1019950029475A KR 19950029475 A KR19950029475 A KR 19950029475A KR 960010635 A KR960010635 A KR 960010635A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
hydrogen
substituted phenyl
trifluoromethyl
Prior art date
Application number
KR1019950029475A
Other languages
English (en)
Inventor
길모어 제레미
태데우스 갤라퍼 피터
빅터 마일스 마틴
마틴 오우튼 윌리암
윌리암 스미스 콜린
Original Assignee
티. 알. 크라우더
릴리 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418326A external-priority patent/GB9418326D0/en
Priority claimed from GBGB9511166.2A external-priority patent/GB9511166D0/en
Application filed by 티. 알. 크라우더, 릴리 인더스트리즈 리미티드 filed Critical 티. 알. 크라우더
Publication of KR960010635A publication Critical patent/KR960010635A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Gyroscopes (AREA)
  • Optical Integrated Circuits (AREA)

Abstract

하기 일반식(Ⅰ)의 약제학적 화합물 및 이의 염 및 용매화물이 기술되어 있다.
상기 식에서, R1및 R7은 각각 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시,임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R2및 R3는 각각 수소 또는 C1-6알킬이며, R4및 R5는 각각 수소, 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시, 임의로 치환된 페닐, 임의로 치환된 나프틸, 암의로 치환된 헤테로아릴, 임의로 치환된 페닐-C1-6알킬 또는 CO2R8(여기서, R8은 에스테르 그룹이다)이며, m및 p 는 각각 0,1,2,3,또는 4이고, Z는또는[여기서, R9및 R10은 각각 수소,C1-6알킬 또는 임의호 치환된 페닐-C1-6알킬이다]이고,X는 산소 또는 황이며, Y 는또는[여기서,R11및 R12는 각각 수소, C1-6알킬, 트리플루오르메틸, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이다]이다.

Description

약제학적 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(Ⅰ)의 약제학적 화합물 및 이의 염 및 용매화물.
    상기 식에서, R1및 R7은 각각 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시,임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R2및 R3는 각각 수소 또는 C1-6알킬이며, R4및 R5는 각각 수소, 할로, 트리플루오로메틸, C1-6알킬, C1-6알콕시, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이고, R6는 수소 C1-6알킬, 임의로 치환된 페닐 임의로 치환된 나프틸, 임의로 치환된 헤테로아릴, 임의로 치환된 페닐-C1-6알킬 또는 CO2R8(여기서, R8은 에스테르 그룹이다)이며, m및 p 는 각각 0,1,2,3,또는 4이고, Z는또는[여기서, R9및 R10은 각각 수소,C1-6알킬 또는 임의호 치환된 페닐-C1-6알킬이다]이고,X는 산소 또는 황이며, Y 는또는[여기서,R11및 R12는 각각 수소, C1-6알킬, 트리플루오르메틸, 임의로 치환된 페닐, 임의로 치환된 나프틸 또는 임의로 치환된 헤테로아릴이다]이다.
  2. 제1항에 있어서, 하기 일반식(Ⅱ)의 화합물.
  3. 제2항에 있어서, X가 산소인 화합물.
  4. 제3항에 있어서,Z가이고, R6가 수소 또는 C1-6알킬인 화합물.
  5. 제1항에 있어서, Z가이고, X가 산소이며, R9가 수소 또는 C1-6알킬이고, m이 0,1 또는 2이며, n이 1 또는 2 이고, R4, R5및 R6가 수소인 화합물.
  6. 하기 일반식의 화합물 및 이의 염.
    상기 식에서, R9는 수소 또는 C1-6알킬이고, R1´,R1˝,R7´및 R7˝은 각각 수소, 할로, C1-6알킬 또는 C1-6알콕시이며, R5는 수소 또는 트리플루오로메틸이고, Y는또는이다.
  7. 제1항에 따른 화합물 또는 이의 약제학적으로 허용되는 염 또는 용매화물을 이의 위한 약제학적으로 허용되는 화석제 또는 담체와 포함하는 약제학적 제형.
  8. 약제로서 사용하기 위한 제1항에 따른 화합물 및 이의 약제학적으로 허용되는 염 또는 용매화물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950029475A 1994-09-12 1995-09-11 약제학적 화합물 KR960010635A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418326.6 1994-09-12
GB9418326A GB9418326D0 (en) 1994-09-12 1994-09-12 Pharmaceutical compounds
GB9511166.2 1995-06-02
GBGB9511166.2A GB9511166D0 (en) 1995-06-02 1995-06-02 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
KR960010635A true KR960010635A (ko) 1996-04-20

Family

ID=26305611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950029475A KR960010635A (ko) 1994-09-12 1995-09-11 약제학적 화합물

Country Status (22)

Country Link
EP (1) EP0705832B1 (ko)
JP (1) JPH0881464A (ko)
KR (1) KR960010635A (ko)
CN (1) CN1045602C (ko)
AT (1) ATE247114T1 (ko)
AU (1) AU698580B2 (ko)
CA (1) CA2157998A1 (ko)
CZ (1) CZ286565B6 (ko)
DE (1) DE69531476T2 (ko)
ES (1) ES2204932T3 (ko)
FI (1) FI954243A (ko)
HU (1) HU219491B (ko)
IL (1) IL115236A (ko)
IN (1) IN179550B (ko)
MY (1) MY132009A (ko)
NO (1) NO305174B1 (ko)
NZ (1) NZ272961A (ko)
PE (1) PE41796A1 (ko)
PH (1) PH31631A (ko)
PL (1) PL310373A1 (ko)
RU (1) RU2146256C1 (ko)
TR (1) TR199501114A2 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2002024661A2 (en) * 2000-09-19 2002-03-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
JP5062939B2 (ja) * 2000-09-19 2012-10-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
ATE306486T1 (de) * 2001-08-08 2005-10-15 Pharmacia & Upjohn Co Llc Therapeutische 1h-pyrido(4,3-b)indole
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
CN102428080A (zh) * 2009-05-29 2012-04-25 住友化学株式会社 神经营养因子活性参与的疾病的治疗或预防剂
KR20240142622A (ko) * 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035369A (en) 1975-10-08 1977-07-12 Janssen Pharmaceutica N.V. 1-Benzazolylalkyl-4-substituted-piperidines
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
FR2661177A1 (fr) * 1990-04-23 1991-10-25 Rhone Poulenc Sante Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant.

Also Published As

Publication number Publication date
TR199501114A2 (tr) 1996-10-21
AU3049795A (en) 1996-03-28
PH31631A (en) 1999-01-12
IL115236A0 (en) 1995-12-31
PE41796A1 (es) 1996-10-21
AU698580B2 (en) 1998-11-05
DE69531476T2 (de) 2004-06-09
NO953575L (no) 1996-03-13
CZ232295A3 (en) 1996-03-13
JPH0881464A (ja) 1996-03-26
ATE247114T1 (de) 2003-08-15
CN1045602C (zh) 1999-10-13
PL310373A1 (en) 1996-03-18
DE69531476D1 (de) 2003-09-18
ES2204932T3 (es) 2004-05-01
CN1129219A (zh) 1996-08-21
EP0705832A1 (en) 1996-04-10
CA2157998A1 (en) 1996-03-13
MY132009A (en) 2007-09-28
NZ272961A (en) 1998-02-26
IL115236A (en) 1998-06-15
RU2146256C1 (ru) 2000-03-10
HUT72593A (en) 1996-05-28
FI954243A0 (fi) 1995-09-11
NO953575D0 (no) 1995-09-11
HU9502631D0 (en) 1995-11-28
EP0705832B1 (en) 2003-08-13
FI954243A (fi) 1996-03-13
HU219491B (hu) 2001-04-28
NO305174B1 (no) 1999-04-12
IN179550B (ko) 1997-10-18
CZ286565B6 (cs) 2000-05-17

Similar Documents

Publication Publication Date Title
KR960010635A (ko) 약제학적 화합물
AU537414B2 (en) Pyroglutamic acid derivatives
DE122005000058I1 (de) Depsipeptide, Herstellung und Anwendung
KR960007592A (ko) 신규한 피롤로카바졸
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
ES2129123T3 (es) Nuevo derivado de bisoxadiazolidina.
DE3862791D1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
KR900701795A (ko) 티에노시클로 헵타피리다진 화합물과 그것의 의약용도
ATE56967T1 (de) Amidderivate.
KR890008151A (ko) 키놀린 카르복산의 유도체
KR870006043A (ko) 피라진유도체 그 제조방법 및 약제조성물
ATE43594T1 (de) 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl(od r thienyl)-methyl-propylamine, ihre herstellung und diese enthaltende pharmazeutische mittel.
KR890003718A (ko) N- 알킬벤젠 술포닐 카르바모일-5- 클로로이소티아졸 유도체 및 살미생물제
ES556048A0 (es) Un procedimiento para la preparacion de un derivado de tiazolidina.
KR920002613A (ko) 이환성 함유 황화합물
KR860007876A (ko) 제초제 조성물
DE69018741D1 (de) Konjugierte gamma-Hydroxybutenolid-Derivate und sie als aktiver Wirkstoff enthaltende Mittel gegen Magengeschwüre.
NO155242C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-(substituert alkyl)-n-(1,3-dithiolan-2-yliden) aniliner.
KR920006354A (ko) 피라졸로퀴놀린 유도체
ATE67197T1 (de) Thiadiazinon-derivate.
KR890006592A (ko) 생리활성을 가진 피라졸 유도체 및 그 제조방법
ATE87004T1 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19950911

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20000907

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19950911

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20020927

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20021217

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20020927

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I